CN111542334B - 用于预防或治疗心律失常的药物组合物 - Google Patents
用于预防或治疗心律失常的药物组合物 Download PDFInfo
- Publication number
- CN111542334B CN111542334B CN201880077650.2A CN201880077650A CN111542334B CN 111542334 B CN111542334 B CN 111542334B CN 201880077650 A CN201880077650 A CN 201880077650A CN 111542334 B CN111542334 B CN 111542334B
- Authority
- CN
- China
- Prior art keywords
- ccn5
- protein
- nucleotide sequence
- sequence encoding
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170127550 | 2017-09-29 | ||
| KR10-2017-0127550 | 2017-09-29 | ||
| PCT/KR2018/011529 WO2019066556A1 (ko) | 2017-09-29 | 2018-09-28 | 심장 부정맥의 예방 또는 치료용 약학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111542334A CN111542334A (zh) | 2020-08-14 |
| CN111542334B true CN111542334B (zh) | 2024-01-23 |
Family
ID=65902177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880077650.2A Active CN111542334B (zh) | 2017-09-29 | 2018-09-28 | 用于预防或治疗心律失常的药物组合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11761019B2 (enExample) |
| EP (1) | EP3689363A4 (enExample) |
| JP (1) | JP7178118B2 (enExample) |
| KR (2) | KR20190038425A (enExample) |
| CN (1) | CN111542334B (enExample) |
| WO (1) | WO2019066556A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7240749B2 (ja) * | 2017-09-29 | 2023-03-16 | ベスファジェン・インコーポレイテッド | 心不全の予防または治療のための医薬組成物 |
| KR20240173703A (ko) * | 2023-06-05 | 2024-12-13 | (주)벳바젠 | 포스포람반의 단백질 포스파타아제 1-매개 탈인산화 억제용 데코이 펩타이드를 암호화하는 뉴클레오타이드 및 ccn5 단백질 또는 이의 단편을 암호화하는 뉴클레오타이드를 포함하는 유전자 컨스트럭트 및 이의 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105452458A (zh) * | 2013-06-07 | 2016-03-30 | 加利福尼亚大学董事会 | 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 |
| WO2017082701A1 (ko) * | 2015-11-13 | 2017-05-18 | (주)벳바젠 | 심장 섬유증 치료용 약제학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US20090239940A1 (en) | 1997-07-22 | 2009-09-24 | Del Monte Federica | Treating heart failure and ventricular arrhythmias |
| EP1382347A1 (en) * | 2002-07-17 | 2004-01-21 | UNIVERSITE PARIS 7 - Denis DIDEROT | Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| US20040106954A1 (en) * | 2002-11-15 | 2004-06-03 | Whitehurst Todd K. | Treatment of congestive heart failure |
| WO2006007444A2 (en) | 2004-06-16 | 2006-01-19 | The Trustees Of Columbia University In The City Of New York | CaMKII/CALCIUM CHANNEL BINDING-RELATED COMPOSITIONS AND METHODS |
| KR101187814B1 (ko) * | 2010-03-22 | 2012-10-08 | 광주과학기술원 | 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법 |
-
2018
- 2018-09-28 WO PCT/KR2018/011529 patent/WO2019066556A1/ko not_active Ceased
- 2018-09-28 KR KR1020180115954A patent/KR20190038425A/ko not_active Ceased
- 2018-09-28 EP EP18861445.7A patent/EP3689363A4/en active Pending
- 2018-09-28 US US16/651,889 patent/US11761019B2/en active Active
- 2018-09-28 CN CN201880077650.2A patent/CN111542334B/zh active Active
- 2018-09-28 JP JP2020518033A patent/JP7178118B2/ja active Active
-
2019
- 2019-07-16 KR KR1020190085741A patent/KR20190087376A/ko not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105452458A (zh) * | 2013-06-07 | 2016-03-30 | 加利福尼亚大学董事会 | 用于治疗心力衰竭和增加心脏功能的不能产生环腺苷酸的腺苷酸环化酶和组合物和方法 |
| WO2017082701A1 (ko) * | 2015-11-13 | 2017-05-18 | (주)벳바젠 | 심장 섬유증 치료용 약제학적 조성물 |
Non-Patent Citations (4)
| Title |
|---|
| High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice;Jin Hee Kim等;《PLoS One》;第6卷(第4期);第e18556页 * |
| Matricellular Protein CCN5 Reverses Established Cardiac Fibrosis;Dongtak Jeong等;《J Am Coll Cardiol》;第67卷(第13期);第1556-1568页 * |
| Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease;Robert G Gourdie等;《Nat Rev Drug Discov》;第15卷(第9期);第620-638页 * |
| The matricellular protein CCN5 prevents adverse atrial structural and electrical remodelling;Min-Ah Lee等;J Cell Mol Med;第24卷(第20期);第11768-11778页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020535203A (ja) | 2020-12-03 |
| KR20190087376A (ko) | 2019-07-24 |
| US11761019B2 (en) | 2023-09-19 |
| EP3689363A1 (en) | 2020-08-05 |
| RU2020114946A (ru) | 2021-10-29 |
| WO2019066556A1 (ko) | 2019-04-04 |
| US20200263200A1 (en) | 2020-08-20 |
| KR20190038425A (ko) | 2019-04-08 |
| CN111542334A (zh) | 2020-08-14 |
| JP7178118B2 (ja) | 2022-11-25 |
| RU2020114946A3 (enExample) | 2021-11-11 |
| EP3689363A4 (en) | 2021-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100137202A1 (en) | Compositions for reprogramming a cell and uses therefor | |
| EP1471926B1 (en) | Compositions and methods for the therapeutic use of an atonal-associated sequence | |
| JP6960396B2 (ja) | 分裂終了細胞の細胞分裂を誘発するための方法 | |
| KR20190035666A (ko) | 심장 섬유증 치료용 약제학적 조성물 | |
| CN111542334B (zh) | 用于预防或治疗心律失常的药物组合物 | |
| EP2477646B1 (en) | Fusion proteins for use in the prevention or treatment of liver failure | |
| ES2376239T3 (es) | Procedimiento de cultivo de células mioc�?rdicas. | |
| US9855315B2 (en) | Pharmaceutical composition comprising CCN5 for reducing cardiac fibrosis in a subject in need thereof | |
| RU2778806C2 (ru) | Фармацевтическая композиция для профилактики или лечения аритмии сердца | |
| KR102044530B1 (ko) | Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물 | |
| CN111465697B (zh) | 用于预防或治疗心力衰竭的药物组合物 | |
| RU2788124C2 (ru) | Фармацевтическая композиция для профилактики или лечения сердечной недостаточности | |
| JP2025517333A (ja) | 心臓疾患を治療するための組成物および方法 | |
| EP2879692B1 (en) | Means for treating heart disease | |
| CN115957301A (zh) | 一种促进心梗心肌修复的细胞分泌因子及应用 | |
| US20040002149A1 (en) | Control of the ratio of LAP to LIP | |
| CN112739370A (zh) | 包含nkx3.2及其片段作为活性成分的治疗视网膜疾病的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |